Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis.
Phase 1
Recruiting
- Conditions
- Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-508284-77-00
- Lead Sponsor
- Alexion Pharmaceuticals Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 254
Inclusion Criteria
Must be = 18 years of age at the time of signing the informed consent, Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV , Positive serological test for autoantibodies against AChR.
Exclusion Criteria
History of thymectomy or any other thymic surgery within 12 months prior to Screening, Untreated thymic malignancy, carcinoma, or thymoma, History of Neisseria meningitidis infection, Pregnancy, breastfeeding, or intention to conceive during the course of the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method